FTM
First Turn Management Portfolio holdings
AUM
$536M
This Quarter Return
-0.25%
1 Year Return
+36.36%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$496M
AUM Growth
+$496M
(-11%)
Cap. Flow
-$27.5M
Cap. Flow
% of AUM
-5.54%
Top 10 Holdings %
Top 10 Hldgs %
46.81%
Holding
44
New
8
Increased
12
Reduced
13
Closed
9
Top Buys
| 1 |
Boston Scientific
BSX
|
$18M |
| 2 |
TG Therapeutics
TGTX
|
$15.8M |
| 3 |
Guardant Health
GH
|
$13.5M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$13.4M |
| 5 |
Insulet
PODD
|
$13M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$24.6M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$23.2M |
| 3 |
Geron
GERN
|
$13.8M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$13.1M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vaxcyte
PCVX
$4.09B
| $10.5M | 2.11% |
276,905
| – | – |
|
27
Apogee Therapeutics
APGE
$2.24B
| $8.58M | 1.73% |
229,675
-23,050
| -9% | -$861K |
|
28
ARS Pharmaceuticals
SPRY
$1.12B
| $8.42M | 1.7% |
669,010
+75,719
| +13% | +$953K |
|
|
BPMC
29
DELISTED
Blueprint Medicines
BPMC
| $8.15M | 1.64% |
92,033
+24,890
| +37% | +$2.2M |
|
30
RadNet
RDNT
$5.44B
| $7.84M | 1.58% |
+157,615
| New | +$7.84M |
|
31
HealthEquity
HQY
$7.7B
| $7.42M | 1.5% |
83,966
-41,901
| -33% | -$3.7M |
|
32
MoonLake Immunotherapeutics
MLTX
$3.66B
| $7M | 1.41% |
+179,196
| New | +$7M |
|
33
Harrow
HROW
$1.4B
| $5.02M | 1.01% |
188,829
-116,045
| -38% | -$3.09M |
|
34
Praxis Precision Medicines
PRAX
$941M
| $2.72M | 0.55% |
71,775
+26,239
| +58% | +$994K |
|
35
Soleno Therapeutics
SLNO
$3.61B
| $2.08M | 0.42% |
+29,115
| New | +$2.08M |
|
36
Arcellx
ACLX
$3.88B
| – | – |
-152,356
| Closed | -$11.7M |
|
37
Biohaven
BHVN
$1.69B
| – | – |
-262,442
| Closed | -$9.8M |
|
38
CorMedix
CRMD
$1.09B
| – | – |
-1,021,421
| Closed | -$8.27M |
|
|
39
Crinetics Pharmaceuticals
CRNX
$3.08B
| – | – |
-453,376
| Closed | -$23.2M |
|
|
40
Day One Biopharmaceuticals
DAWN
$767M
| – | – |
-947,878
| Closed | -$12M |
|
|
41
Geron
GERN
$932M
| – | – |
-3,893,327
| Closed | -$13.8M |
|
42
Syndax Pharmaceuticals
SNDX
$1.41B
| – | – |
-441,587
| Closed | -$5.84M |
|
|
BCAX
43
Bicara Therapeutics Inc. Common Stock
BCAX
$637M
| – | – |
-346,170
| Closed | -$6.03M |
|
|
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-294,414
| Closed | -$24.6M |
|